Pharmacokinetic interactions of herbal medicines for the treatment of chronic hepatitis

Hsueh, Tun-Pin; Lin, Weigan; Tsai, Tung Hu

doi:10.1016/j.jfda.2016.11.010

Cited by 19 publications

(14 citation statements)

References 81 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The oral administration of loganin described in this study was characterized by a non-invasive therapeutic approach in comparison to that of previous reports [40], which regarded loganin as an oral therapeutic agent against osteoarthritis. In addition, regarding the pharmacologic efficacy and drug bioavailability, metabolomic profiles, such as plasma concentration, should be used to evaluate drug properties [41]. The plasma concentrations of loganin were eliminated within 4 h after oral administration of loganin.…”

Section: Discussionmentioning

confidence: 99%

Ameliorative Effects of Loganin on Arthritis in Chondrocytes and Destabilization of the Medial Meniscus-Induced Animal Model

et al. 2021

View full text Add to dashboard Cite

Arthritis is a common inflammatory disease that causes pain, stiffness, and joint swelling. Here, we investigated the ameliorative effects of loganin on arthritis in vitro and in vivo. A single bioactive compound was fractionated and isolated from Cornus officinalis (CO) extract to screen for anti-arthritic effects. A single component, loganin, was identified as a candidate. The CO extract and loganin inhibited the expression of factors associated with cartilage degradation, such as cyclooxygenase-2 (COX-2), matrix metalloproteinase 3 (MMP-3), and matrix metalloproteinase 13 (MMP-13), in interukin-1 beta (IL-1β)-induced chondrocyte inflammation. In addition, prostaglandin and collagenase levels were reduced following treatment of IL-1β-induced chondrocytes with loganin. In the destabilization of the medial meniscus (DMM)-induced mouse model, loganin administration attenuated cartilage degeneration by inhibiting COX-2, MMP-3, and MMP-13. Transverse micro-CT images revealed that loganin reduced DMM-induced osteophyte formation. These results indicate that loganin has protective effects in DMM-induced mice.

show abstract

Section: Discussionmentioning

confidence: 99%

Ameliorative Effects of Loganin on Arthritis in Chondrocytes and Destabilization of the Medial Meniscus-Induced Animal Model

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Since herbal products have been shown to have therapeutic properties and because their use has become more prevalent in the context of chronic liver disease, the safety of combined treatment with herbal products and conventional medicines should not be ignored. Previous articles revealed possible herb-drug interactions of traditional herbal formulas for chronic hepatitis with conventional drugs [29,30]. For instance, herbal products could delay the elimination of 5-FU in blood or change the bioavailability of carbamazepine [31,32].…”

Section: Introductionmentioning

confidence: 99%

Preclinical study of simultaneous pharmacokinetic and pharmacodynamic herb-drug interactions between Yin-Chen-Hao-Tang and spironolactone

Hsueh

Tsai²

2020

BMC Complement Med Ther

Self Cite

View full text Add to dashboard Cite

Background: The prevalence and therapeutic effects of the use of herbal remedies for chronic liver diseases make the combined administration of herbal products with conventional treatment unable to be ignored. This study investigated the pharmacokinetic and pharmacodynamic herb-drug interactions between the herbal formula Yin-Chen-Hao-Tang (YCHT) and spironolactone. Methods: A selective high-performance liquid chromatography (HPLC) method was developed and validated for the detection of spironolactone and its metabolite canrenone in rat urine. The interaction study was conducted by collecting urine samples after oral administration of spironolactone alone or in combination with YCHT for 5 days. Urine pharmacokinetic parameters and urinary sodium, potassium, volume, and weight were analyzed. Results: The results revealed significant increases in the cumulative amount and the area under the rate curve (AURC) of the metabolite canrenone after pretreatment with the high dose of YCHT. The urine weight and volume were significantly reduced dose-dependently as a result of pretreatment with YCHT. The urinary sodium-topotassium ratio, which indicates diuretic effects, was also reduced in the high-dose YCHT condition. Conclusions: Herb-drug pharmacokinetic and pharmacodynamic interactions between YCHT and spironolactone were observed in the study. The herb-drug interaction that appeared with a single dose of spironolactone should be considered when patients are being treated with a continuous administration of this drug.

show abstract

“…5 Various herbal medicines, including formula, extracts and compounds derived from herbs, have been used for treatment of liver diseases, including chronic hepatitis B, chronic hepatitis C (CHC), alcoholic liver disease, and nonalcoholic fatty liver disease. [6][7][8][9][10][11] Over the past few decades, particular attention has been paid to the potential anti-HCV effects of herbal medicines, and most of in vitro (in hepatic cell lines) and in vivo (in animals) studies have shown significant anti-HCV effects for a number of herbal medicines.…”

Section: Introductionmentioning

confidence: 99%

Herbal Medicines for Hepatitis C Virus Infection: The Exploratory Journey from Bench to Bedside Still Has a Long Way to Go

Xiao-ya¹,

Zhang²,

Xie³

et al. 2019

Journal of Exploratory Research in Pharmacology

View full text Add to dashboard Cite

Hepatitis C virus (HCV) infects at least 150 million people chronically worldwide. It is a major risk factor for cirrhosis, hepatocellular carcinoma, and death. Direct-acting antiviral therapy is very efficacious in treating HCV infection but it is inaccessible and unavailable in some developing countries. Therefore, searching for more effective and easily accessible regimens remains an urgent need. The aim of this article is to review the anti-HCV effects of herbal medicines from experimental to clinical evidence, and discuss current issues, hurdles and future perspectives for their application from bench to bedside. Numerous in vitro studies have indicated that many herbs work effectively in exerting anti-HCV activities. Yet, only a few animal experiments have been conducted that demonstrate the anti-HCV effects of these medicines; in addition, these results do not show an ability to eliminate the virus completely from the infected animals. Thus far, clinical trials have produced inconclusive anti-HCV results in terms of efficacy and safety, presumably due to the lack of the quality of methodologies used in the trials. In conclusion, despite apparent anti-HCV activities in vitro, clinical efficacy and safety of herbal medicines for the treatment of HCV infection have not been revealed convincingly. More animal studies using ideal models and more well-designed clinical trials with a larger sample sizes and longer treatment periods, taking the body habitus into consideration, are required to further assess the efficacy and safety of herbal medicines for HCV infection.

show abstract

Pharmacokinetic interactions of herbal medicines for the treatment of chronic hepatitis

Cited by 19 publications

References 81 publications

Ameliorative Effects of Loganin on Arthritis in Chondrocytes and Destabilization of the Medial Meniscus-Induced Animal Model

Ameliorative Effects of Loganin on Arthritis in Chondrocytes and Destabilization of the Medial Meniscus-Induced Animal Model

Preclinical study of simultaneous pharmacokinetic and pharmacodynamic herb-drug interactions between Yin-Chen-Hao-Tang and spironolactone

Herbal Medicines for Hepatitis C Virus Infection: The Exploratory Journey from Bench to Bedside Still Has a Long Way to Go

Contact Info

Product

Resources

About